TET1 and neoplasm: In 2020, Bamezai et al50 showed that PARP enzymes enhanced TET1 expression in T-cell acute lymphoblastic leukemia by creating tri-methylation of histone 3 at lysine 4 (H3K4me3) marks on its promoter, and the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib reduced TET1 expression, 5hmC levels, and tumor growth.